Dr. Shail Maingi, MD

Dr. Maingi practices at Breast Care Center - HOPD in South Weymouth, Massachusetts.

Dr. Maingi's NPI, 1114183795, was assigned on August 1, 2008. Dr. Maingi graduated from Temple University School of Medicine in 2003. Dr. Maingi holds New York license 249730.

Dr. Maingi's primary practice is Breast Care Center - HOPD, at 101 Columbian Street, South Weymouth, MA 02190.

Dr. Maingi's primary practice is Breast Care Center - HOPD in South Weymouth, Massachusetts. Dr. Maingi is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Maingi to 2 more hospitals, 1 home health agency and 1 hospice, each named with a free account. Dr. Maingi's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Maingi practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Maingi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Maingi's licenses on file in 3 states: New York, Massachusetts and New Jersey.

CMS data shows 819 Medicare services from Dr. Maingi across 4 procedure codes in 2024, all of them office visits, for 313 Medicare patients. Medicare paid $84,496 for them. Every service was in an office.

CMS counts 313 Medicare patients who saw Dr. Maingi in 2024. The largest group is 65 to 74, with 132 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Maingi's median patient age at 72, with 74% women.

In 2024, Dr. Maingi wrote 1,229 Medicare Part D claims for 219 patients. 88% of them were for generic drugs. CMS names the drug for 978 of them, across 33 drugs with 11 or more claims each, at $868,729 in total drug cost. In 2023, CMS named 575 claims across 19 drugs.

Dr. Maingi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Maingi as offering telehealth.

Dmand AI links 23 papers to Dr. Maingi, published from 2017 to 2025. 2017 was the busiest year, with 3. The most frequent topics are Sexual and Gender Minorities, Gender Identity and Palliative Care. Dr. Maingi has published most often in Palliat Support Care. Dr. Maingi's most frequent co-authors are Asa E. Radix, MD, Carl G. Streed, MD and Ethan T. Anglemyer, DO.

Dmand AI links Dr. Maingi to 1 clinical trial. Conditions studied include Breast Cancer Lymphedema and Lymphedema.

CMS Open Payments shows 43 general payments to Dr. Maingi from 19 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 66% of the total. AstraZeneca Pharmaceuticals LP paid the most, $4,096.

Dr. Maingi graduated from Temple University School of Medicine in 2003.